N
Nevakar
About Nevakar
Nevakar is a specialized pharmaceutical company that focuses on developing innovative treatments for various medical conditions. The company's main area of operation is the healthcare sector, specifically the pharmaceutical industry. It serves a broad range of clients, including healthcare providers, researchers, regulators, and application developers.
The company's business model revolves around the development and commercialization of novel pharmaceutical products. Its primary source of revenue is the sale of these products to healthcare providers and other related entities. One of its leading compounds is currently in the third phase of a clinical study, known as the CHAMP (Childhood Atropine for Myopia Progression) study. This study aims to develop a treatment for myopia progression in children, indicating the company's commitment to addressing significant health issues.
In addition to its pharmaceutical development, Nevakar also provides machine-readable files in response to the federal Transparency in Coverage Rule. These files include negotiated service rates and out-of-network allowed amounts between health plans and healthcare providers. By formatting these files for easy access and analysis, Nevakar is contributing to increased transparency and understanding in the healthcare sector.
In summary, Nevakar is a pharmaceutical company that develops innovative treatments and promotes transparency in healthcare through the provision of machine-readable data. It operates in the healthcare sector, serving a diverse range of clients and generating revenue through the sale of its pharmaceutical products.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2015
- Headquarters
- Bridgewater, United States
- Employees
- 34
- Open positions
- None listed
- Dealroom signal
- 34.6/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, Arts & Culture, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GROWTH EQUITY VCOther financing | Jun 2019 | $50M | — | NovaQuest Capital Management | ↗ |
| DEBTDebt | Nov 2018 | $30M | — | Oxford Finance | ↗ |
Growth signals
Latest recorded traffic for Nevakar is 1.5K monthly website visits, up 117.4% over the last three months. Nevakar's team declined 5.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later2 investors entered at this stage
Oxford Finance
NovaQuest Capital Management
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Nevakar on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Nevakar’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.